<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669435</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV003DIM2008</org_study_id>
    <nct_id>NCT00669435</nct_id>
  </id_info>
  <brief_title>Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis</brief_title>
  <official_title>Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin II has been proposed as a lipid metabolism regulator. It is known that adipocytes
      secrete a variety of protein, such as TNFα, plasminogen activator inhibitor (PAI)-1, leptin,
      resistin and adiponectin; these proteins have a wide range of biological effects and are
      associated with insulin resistance. Adipocytes also produce angiotensinogen and angiotensin
      II and a local renin-angiotensin system (RAS) is present in adipose tissue. In overweight or
      obese hypertensive normocholesterolemic patients the treatment with AT1-receptor blocker
      (Losartan) may have a better effect on hepatic steatosis and visceral fat deposition than the
      antihypertensive treatment with calcium channel blocker (amlodipine). Simvastatin will be
      added to both groups. The aim of this study is to evaluate the effect of losartan and
      simvastatin on ultrasonographic qualitative and quantitative parameters in overweight or
      obese hypertensive normocholesterolemic patients with hepatic steatosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All patients will undergo anthropometric evaluation and abdominal ultrasonography (performed by the same examiner); will be taken routine liver US and US measurement of visceral and subcutaneous fat.</measure>
    <time_frame>Between 08.00 and 10.00 at baseline, and after 1, 6, and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of insulin sensitivity, leptin, adiponectin, TNFα, IL6, hsPCR</measure>
    <time_frame>Between 08.00 and 10.00 at baseline, and after 1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine and Simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan and Simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan + Simvastatin</intervention_name>
    <description>tablets; 50, 100 mg; od; 12 months
tablets; 20 mg; od; 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine + Simvastatin</intervention_name>
    <description>tablets; 5, 10 mg; od; 12 months
tablets; 20 mg; od; 6 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: 50% Male and 50% female

          -  Age: 40-80 years

          -  Race: Caucasian

          -  Overweight or obese: respectively BMI25-30 kg/m2 or BMI &gt; 30 kg m2

          -  Hypertensive: PA &gt; 140/90 mmHg

          -  Normocholesterolemic (LDL&lt; 160 mg/dl HDL &gt; 35 mg/dl)

          -  Liver steatosis

        Exclusion Criteria:

          -  other antihypertensive treatment after wash out period of 2 weeks

          -  abnormal heart rest function (EF &lt; 55%).

          -  valvular heart disease

          -  congenital heart disease

          -  heart failure or prior myocardial infarction

          -  diabetes

          -  renal disease

          -  liver disease

          -  connective tissue disease

          -  pregnancy or lactation

          -  serious adverse experience

          -  sensitivity to the study drugs or its components

          -  contraindication from an approved label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Derosa</last_name>
    <phone>39-038-250-2614</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD</last_name>
      <phone>39-038-250-2614</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>April 28, 2008</last_update_submitted>
  <last_update_submitted_qc>April 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Giuseppe Derosa/MD</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Liver steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

